All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dostarlimab Elicits Clinical Complete Response Among All Treated Patients with dMMR Rectal Cancer

June 7th 2022

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

Adjuvant Pembrolizumab Demonstrates DFS Benefit in Key Subgroups of Resected Early-Stage NSCLC

June 7th 2022

Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.

Significant Enrichment of CDKN2A/B Alterations Found in Patients With NSCLC and Brain Mets

June 7th 2022

Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.

FOLFOXIRI Plus Bevacizumab Improves PFS, ORR at Expense of Increased Toxicity in CRC Liver Metastases

June 7th 2022

FOLFOXIRI plus bevacizumab led to a significant improvement in progression-free survival, objective response rate, and R0/1 resections vs FOLFOX/FOLFIRI plus bevacizumab but resulted in increased toxicity in patients with initially unresectable colorectal cancer liver metastases and right-sided and/or RAS- or BRAF V600E–mutated primary tumors.

Darolutamide Does Not Affect Cabazitaxel Systemic Exposure in mCRPC

June 7th 2022

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

Lasofoxifene/Abemaciclib Shows Acceptable Safety, Promising Efficacy in Previously Treated, ESR1-Mutated Metastatic Breast Cancer

June 6th 2022

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Ribociclib Shows Superior QOL With Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

June 6th 2022

Ribociclib plus an aromatase inhibitor elicited improved symptom-related quality of life outcomes compared with abemaciclib plus an aromatase inhibitor as first-line therapy in postmenopausal patients with hormone receptor–positive, HER2–negative advanced breast cancer, according to findings from a matching-adjusted indirect comparison study.

Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer

June 6th 2022

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

Frontline Bevacizumab Plus Chemotherapy Elicits PFS, OS Benefit in Ovarian Clear Cell Carcinoma

June 6th 2022

Bevacizumab combined with first-line chemotherapy was shown to improve progression-free survival and overall survival in patients with advanced ovarian clear cell carcinoma.

Pembrolizumab Triplet Prolongs PFS and OS Across Subgroups in Persistent, Recurrent, and Metastatic Cervical Cancer

June 6th 2022

Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.

Frontline Nivolumab/Ipilimumab Plus Chemotherapy Sustains Survival Benefit in Metastatic NSCLC

June 6th 2022

Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.

Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status

June 6th 2022

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

Ruxolitinib Plus Chemo as Pre/Postsurgical Treatment Prolongs PFS in Ovarian Cancer

June 6th 2022

Twice-daily oral ruxolitinib plus carboplatin and paclitaxel given as frontline neoadjuvant and post-surgical treatment to patients with stage III or IV ovarian cancer was found to be feasible and to improve progression-free survival compared with chemotherapy alone.

Patritumab Deruxtecan Induces Clinical Activity in NSCLC Regardless of Identified Driver Genomic Alterations

June 6th 2022

Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.

Primary Tumor Resection Before Chemo Does Not Prolong OS in Colon Cancer With Synchronous Unresectable Metastases

June 6th 2022

Resection of the primary tumor prior to systemic therapy was not found to extend overall survival in patients with asymptomatic colon and high rectal cancer who had synchronous unresectable metastases.

Age, Menopausal Status, and Lymph Node Involvement Among Variables Associated With Abemaciclib Discontinuation in High-Risk Early Breast Cancer

June 6th 2022

Higher treatment discontinuation rates with abemaciclib were associated with factors including age of 65 year or older, enrollment in either North America or Europe, an ECOG performance status of 1, postmenopausal status, 1 to 3 positive lymph nodes, and 4 or more preexisting comorbidities in patients with hormone receptor–positive, HER2-negative high-risk early breast cancer.

Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC

June 6th 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.

Pathologic Response Is Key Indicator of EFS Benefit With Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

June 6th 2022

Neoadjuvant nivolumab in combination with platinum-based doublet chemotherapy extended event-free survival in patients with stage IB-IIA non–small cell lung cancer who had pathologic complete response, according to a post hoc analysis of the phase 3 CheckMate 816 trial.

Capmatinib Plus Pembrolizumab Does Not Provide Clinical Benefit in MET Unselected, PD-L1-high Expressing NSCLC

June 6th 2022

The addition of the MET inhibitor capmatinib to pembrolizumab failed to improve clinical outcomes in patients with treatment-naïve non–small cell lung cancer with PD-L1 expression of at least 50% vs pembrolizumab alone, according to an analysis of outcomes of patients in the MET unselected population treated in a phase 2 trial.

Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer

June 6th 2022

Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.